RxDoctor Payments Data

Ashley Bevins, DO

Internal Medicine · Norton, VANPI 1275726069

Payments from drug & device makers

$10,988in general payments, 2019–2025

Across 753 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$915
  • Lilly USA, LLC$866
  • Amgen$843
  • Abbott$649
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$10,988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,988 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$165,921
Medicare patients
221
Services billed
2,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban273$215,873
OzempicSemaglutide117$153,193
MounjaroTirzepatide71$79,425
LinzessLinaclotide74$69,092
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$44,189
JardianceEmpagliflozin40$36,513
FarxigaDapagliflozin Propanediol35$33,853
MyrbetriqMirabegron45$32,747
TrulicityDulaglutide28$28,602
XareltoRivaroxaban31$23,479
RybelsusSemaglutide17$22,376
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$21,168
WegovySemaglutide15$19,379
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$17,651
Repatha SureclickEvolocumab24$17,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$396$215,873273 claims
Novo NordiskOzempic, Rybelsus, Wegovy$1,663$194,948149 claims
Lilly USA, LLCMounjaro, Trulicity$866$108,02699 claims
AbbVieLinzess, Synthroid$915$72,689140 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,234$64,750108 claims
GSKTrelegy Ellipta$567$44,18958 claims
Boehringer IngelheimJardiance, Tradjenta$150$43,57652 claims
Astellas Pharma US IncMyrbetriq$186$32,74745 claims
Johnson & JohnsonXarelto$325$23,47931 claims
MerckLagevrio (Eua)$158$7,56415 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$320$5,53712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Norton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →